Clene Inc (NASDAQ:CLNNW) — Market Cap & Net Worth
Market Cap & Net Worth: Clene Inc (CLNNW)
Clene Inc (NASDAQ:CLNNW) has a market capitalization of $17.65 ($17.65) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #31807 globally and #6308 in its home market, demonstrating a -66.04% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Clene Inc's stock price $0.00 by its total outstanding shares 9803 (9.80K). Review CLNNW liabilities breakdown to assess the company's total debt and financial obligations.
Clene Inc Market Cap History: 2018 to 2025
Clene Inc's market capitalization history from 2018 to 2025. Data shows change from $1.96K to $17.65 (-46.97% CAGR).
Clene Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Clene Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Clene Inc's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $9.80K | $206.00K | -$19.28 Million | 0.05x | N/A |
| 2021 | $4.24K | $723.00K | -$9.74 Million | 0.01x | N/A |
| 2022 | $245.07 | $473.00K | -$29.92 Million | 0.00x | N/A |
| 2023 | $413.69 | $654.00K | -$49.50 Million | 0.00x | N/A |
| 2024 | $490.15 | $342.00K | -$39.40 Million | 0.00x | N/A |
Competitor Companies of CLNNW by Market Capitalization
Companies near Clene Inc in the global market cap rankings as of June 18, 2026.
Key companies related to Clene Inc by market ranking:
- US Solar Fund PLC (LSE:USFP): Ranked #31798 globally with a market cap of $29.81 USD ( GBX245.04K GBX).
- Lion Financial Group Limited (NASDAQ:LGHLW): Ranked #31799 globally with a market cap of $29.69 USD.
- Jasmine International Public Company Limited (F:JASN): Ranked #31808 globally with a market cap of $16.69 USD ( €14.28 EUR).
- Lexaria Bioscience Corp (NASDAQ:LEXXW): Ranked #31809 globally with a market cap of $11.23 USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #31798 | US Solar Fund PLC | LSE:USFP | $29.81 | GBX27.10 |
| #31799 | Lion Financial Group Limited | NASDAQ:LGHLW | $29.69 | $0.00 |
| #31808 | Jasmine International Public Company Limited | F:JASN | $16.69 | €0.00 |
| #31809 | Lexaria Bioscience Corp | NASDAQ:LEXXW | $11.23 | $0.00 |
Clene Inc Historical Marketcap From 2018 to 2025
Between 2018 and today, Clene Inc's market cap moved from $1.96K to $ 17.65, with a yearly change of -46.97%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $17.65 | -96.40% |
| 2024 | $490.15 | +18.48% |
| 2023 | $413.69 | +68.80% |
| 2022 | $245.07 | -94.21% |
| 2021 | $4.24K | -56.79% |
| 2020 | $9.80K | +1563.89% |
| 2019 | $589.16 | -69.95% |
| 2018 | $1.96K | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Clene Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $17.65 USD |
| MoneyControl | $17.65 USD |
| MarketWatch | $17.65 USD |
| marketcap.company | $17.65 USD |
| Reuters | $17.65 USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Clene Inc
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis … Read more